Proliferating cells, in particular tumor cells, are characterized by a high amount of the dimeric form of the pyruvate kinase isoenzyme type M2 (Tumor M2-PK). Tumor M2-PK can be determined in EDTA ...

Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...

Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The ...

William Blair analyst Sami Corwin has maintained their bullish stance on RCKT stock, giving a Buy rating yesterday. Sami Corwin has given his ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

This study provides convincing evidence for functional subpopulations of β-cells responsible for Ca2+ signal initiation and maintenance using novel three-dimensional light sheet microscopy imaging and ...

2022 — Results from a phase 3 clinical indicate that the oral drug mitapivat is safe and effective for treating adults with pyruvate kinase deficiency, a ... Jan. 14, 2022 — A world-first ...

CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

Equities researchers at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Agios Pharmaceuticals ...

Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET. Company Participants. Chris Taylor - Vice President, Investor Relations and ...

Mirae Asset Global Investments Co. Ltd. raised its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 21.5% during the third quarter, according to its most recent filing with the ...

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel ...